Evoke Pharma and EVERSANA Announce Abstract Selection for Plenary Oral Presentation at The American College of Gastroenterology (ACG) 2023 Annual Meeting
July 25 2023 - 8:30AM
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical
company focused primarily on treatments for gastrointestinal (GI)
diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray,
and EVERSANA™, a leading provider of global commercial services to
the life science industry, today announced that its abstract
entitled “Superiority of Nasal Spray Compared to Orally
Administered Metoclopramide in Reducing Healthcare Costs in
Treating Diabetic Gastroparesis Patients” will be presented, as an
oral plenary presentation, at the American College of
Gastroenterology annual meeting taking place in Vancouver, BC,
Canada from October 20-25, 2023.
During the meeting, the authors of the abstract,
including Drs. Richard Mccallum (Texas Tech University-El Paso),
Michael Cline (Cleveland Clinic) and David Kunkel (University of
California, San Diego) will review data that demonstrated tangible
and quantifiable benefits of Evoke’s flagship product, GIMOTI, to
reduce healthcare costs.
GIMOTI is the only FDA-approved novel nasal
formulation of metoclopramide commercially available and
specifically designed to deliver a non-oral dose of metoclopramide
for the relief of symptoms in adults with acute and recurrent
diabetic gastroparesis (DGP). Evoke developed Gimoti as a nasal
spray to specifically by-pass erratic absorption issues that DGP
patients often suffer with medications that are in tablet or pill
form. Recent Real World Outcomes data, presented at DDW in May,
demonstrated Gimoti significantly reduced healthcare resource
utilization (i.e., ER visits or hospitalizations) compared to oral
metoclopramide. This new data builds off those findings and explore
the potential to reduce the cost of care for patients with DGP.
“The ACG is the preeminent professional
organization that champions the prevention, diagnosis, and
treatment of digestive disorders, including DGP. As such, the ACG
annual meeting brings together the most revered minds in
gastroenterology and experts in clinical care to guide the delivery
of the highest quality, compassionate, and evidence-based patient
care. We are thrilled and honored to present compelling data
related to cost savings from prescribing GIMOTI compared to the
current standard of care,” said David A. Gonyer, R.Ph., Chief
Executive Officer of Evoke Pharma. “This data continues to affirm
our belief that nasal metoclopramide is the future for treating
diabetic gastroparesis – a disease that approximately 2-3 million
patients in the US alone seek for treatment.”
“This year’s presentation on GIMOTI at ACG 2023 is
particularly exciting as it significantly impacts our commercial
efforts to get the therapy in the hands of those that need it
most,” commented Chris Quesenberry, Chief Commercial Officer for
GIMOTI at EVERSANA. “Patients and healthcare providers deserve
optimal alternatives to treating and managing diabetic
gastroparesis and we believe this event will serve as a great
platform to bring the professional GI community’s attention to the
merits of Evoke’s product.”
Details of the abstract as follows:
Title: Superiority of Nasal Spray
Compared to Orally Administered Metoclopramide in Reducing
Healthcare Costs in Treating Diabetic Gastroparesis Patients
Presentation Number: 67
Presentation Date/Time: Wednesday,
October 25 8:50 A.M. PDT
Location: Vancouver Convention
Centre (West Building)
About Evoke Pharma, Inc.Evoke
is a specialty pharmaceutical company focused primarily on the
development of drugs to treat GI disorders and diseases. The
company developed, commercialized and markets GIMOTI, a nasal spray
formulation of metoclopramide, for the relief of symptoms
associated with acute and recurrent diabetic gastroparesis in
adults. Diabetic gastroparesis is a GI disorder affecting millions
of patients worldwide, in which the stomach takes too long to empty
its contents resulting in serious GI symptoms as well as other
systemic complications. The gastric delay caused by gastroparesis
can compromise absorption of orally administered medications. Prior
to FDA approval to commercially market GIMOTI, metoclopramide was
only available in oral and injectable formulations and remains the
only drug currently approved in the United States to
treat gastroparesis.
Visit www.EvokePharma.com for more
information.Follow GIMOTI on FacebookFollow Evoke
Pharma on FacebookFollow Evoke
Pharma on LinkedInFollow Evoke
Pharma on Twitter
About EVERSANA EVERSANA® is a
leading independent provider of global services to the life
sciences industry. The company’s integrated solutions are rooted in
the patient experience and span all stages of the product life
cycle to deliver long-term, sustainable value for patients,
prescribers, channel partners and payers. The company serves more
than 650 organizations, including innovative start-ups and
established pharmaceutical companies, to advance life sciences
solutions for a healthier world. To learn more about EVERSANA,
visit eversana.com or connect through LinkedIn and Twitter.
Safe Harbor StatementEvoke
cautions you that statements included in this press release that
are not a description of historical facts are forward-looking
statements. In some cases, you can identify forward-looking
statements by terms such as “may,” “will,” “should,” “expect,”
“plan,” “anticipate,” “could,” “intend,” “target,” “project,”
“contemplates,” “believes,” “estimates,” “predicts,” “potential” or
“continue” or the negatives of these terms or other similar
expressions. These statements are based on the company’s current
beliefs and expectations. These forward-looking statements include
statements regarding: GIMOTI’s potential to reduce healthcare
resource utilization by diabetic gastroparesis patents; and Evoke’s
belief that GIMOTI can improve treatment of diabetic gastroparesis.
The inclusion of forward-looking statements should not be regarded
as a representation by Evoke that any of its plans will be
achieved. Actual results may differ from those set forth in this
press release due to the risks and uncertainties inherent in
Evoke’s business, including, without limitation: Evoke’s and
EVERSANA’s ability to successfully drive market demand for GIMOTI;
Evoke’s ability to obtain, maintain and successfully enforce
intellectual property protection for GIMOTI; the results of market
research studies may not predict acceptance by patients, healthcare
providers or payors; inadequate efficacy or unexpected adverse side
effects relating to GIMOTI that could result in recalls or product
liability claims; Evoke’s ability to obtain additional financing as
needed to support its operations; Evoke is entirely dependent on
the success of GIMOTI; Evoke’s dependence on third parties for the
manufacture of GIMOTI; and other risks and uncertainties detailed
in Evoke’s prior press releases and in the periodic reports it
files with the Securities and Exchange Commission. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and Evoke
undertakes no obligation to revise or update this press release to
reflect events or circumstances after the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement. This caution is made under the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995.
Investor Contact:Daniel
Kontoh-BoatengDKB PartnersTel:
862-213-1398dboateng@dkbpartners.net
Evoke Pharma (NASDAQ:EVOK)
Historical Stock Chart
From Apr 2024 to May 2024
Evoke Pharma (NASDAQ:EVOK)
Historical Stock Chart
From May 2023 to May 2024